Synthetic peptides and DNA sequences for treatment of multiple sclerosis
AssigneeAvraham Ben-Nun
InventorsAvraham Ben-Nun, Nicole Kerlero De Rosbo
Life of this patent
Estimating the term…
Abstract
Synthetic unaltered and altered peptides comprising sequences of at least one immunogenic epitope cluster (IEC) of at least one human autoantigen related to multiple sclerosis (MS) and at least one nonameric core sequence which fits into the MS-relevant HLA-DR/DQ molecule and is flanked by 2-5 amino acids at its N- and C-termini, are provided. The alteration is preferably by substituting 1 to 3 TCR contact residues by Ala. The autoantigen is preferably MOG, MBP, OSP, MOBP and PLP. Polypeptides comprising at least two such peptides of a sole autoantigen or at least one peptide of two different autoantigens, and synthetic genes encoding them, are also provided, as well as pharmaceutical compositions for treatment and diagnostic of MS.
Claims4
A synthetic polypeptide comprising amino acid sequences of at least one immunogenic epitope cluster (IEC) of at least two different human autoantigens related to multiple sclerosis (MS) selected from the group consisting of myelin-associated glycoprotein (MAG), myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), myelin-oligodendrocytic basic protein (MOBP), oligodendrocyte-specific protein (OSP) and proteolipid protein (PLP), and wherein said IEC's are altered from their native sequence and are selected from the group consisting of the MOG-AL peptides of SEQ ID NOs:
- 48-53 and 232-233;
- the MBP-AL peptides of SEQ ID NOs:
- 54-61;
- the OSP-AL peptides of SEQ ID NOs:
- 62-69;
- the MOBP-AL peptides of SEQ ID NOs:
- 70-73;
- and
- the PLP-AL peptides of SEQ ID NOs:
- 74-86.
Dependencies are inferred from the claim text.